Pulmonx Future Growth
Future criteria checks 1/6
Pulmonx is forecast to grow earnings and revenue by 11.5% and 15.3% per annum respectively. EPS is expected to grow by 12.8% per annum. Return on equity is forecast to be -37.7% in 3 years.
Key information
11.5%
Earnings growth rate
12.8%
EPS growth rate
| Medical Equipment earnings growth | 16.2% |
| Revenue growth rate | 15.3% |
| Future return on equity | -37.7% |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Apr 04
Pulmonx: Revisiting Thesis Following Management Change
Mar 26Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Feb 23Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues
Aug 01Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically
Nov 08Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M
Aug 02Pulmonx: Interesting Technology But Struggling With Adoption
Jul 02These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$62.20
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 117 | -58 | N/A | N/A | 5 |
| 12/31/2025 | 97 | -65 | N/A | N/A | 5 |
| 12/31/2024 | 82 | -72 | -44 | N/A | 5 |
| 12/31/2023 | 69 | -61 | -38 | -38 | N/A |
| 9/30/2023 | 65 | -61 | -40 | -39 | N/A |
| 6/30/2023 | 61 | -61 | -42 | -41 | N/A |
| 3/31/2023 | 57 | -59 | -44 | -43 | N/A |
| 12/31/2022 | 54 | -59 | -46 | -45 | N/A |
| 9/30/2022 | 52 | -58 | -48 | -46 | N/A |
| 6/30/2022 | 52 | -54 | -47 | -44 | N/A |
| 3/31/2022 | 50 | -52 | -51 | -47 | N/A |
| 12/31/2021 | 48 | -49 | -45 | -41 | N/A |
| 9/30/2021 | 45 | -45 | -41 | -38 | N/A |
| 6/30/2021 | 42 | -39 | -37 | -35 | N/A |
| 3/31/2021 | 33 | -38 | -32 | -30 | N/A |
| 12/31/2020 | 33 | -32 | -32 | -31 | N/A |
| 9/30/2020 | 33 | -28 | -27 | -27 | N/A |
| 6/30/2020 | 32 | -28 | -26 | -25 | N/A |
| 3/31/2020 | 35 | -22 | -25 | -24 | N/A |
| 12/31/2019 | 33 | -21 | -21 | -21 | N/A |
| 12/31/2018 | 20 | -18 | -19 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUNG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LUNG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LUNG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LUNG's revenue (15.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: LUNG's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LUNG is forecast to be unprofitable in 3 years.